Antiruisi Attenuates Atherosclerosis in High-Fat-Diet-Fed ApoE−/− Mice and Is Associated with Alterations in the Gut Microbiota
Atherosclerosis is a leading cause of cardiovascular morbidity and mortality, and the gut microbiota is a potential therapeutic target. Antiruisi (ATRS) is a fixed-ratio combination of natural-product-derived active ingredients. In this study, 24 male ApoE−/− mice were assigned to normal chow, high-fat diet (HFD), HFD plus atorvastatin, or HFD plus ATRS groups (n = 6 per group) and treated for 12 weeks. ATRS improved serum lipid profiles, reduced atherosclerotic plaque area, and attenuated hepatic steatosis and lipid accumulation. ATRS also altered gut microbial composition, reduced circulating trimethylamine N-oxide levels and hepatic flavin-containing monooxygenase 3 expression, modulated the farnesoid X receptor, fibroblast growth factor 15, and cholesterol 7α-hydroxylase expression, and regulated p38 mitogen-activated protein kinase and nuclear factor-kappa B expression, as well as associated inflammatory marker levels. These findings suggest that ATRS attenuates atherosclerosis in HFD-fed ApoE−/− mice, with accompanying changes in gut microbiota composition and metabolic and inflammatory markers.
Authors
- Shasha Li
- Zunjing Liu
Institutions
- Hebei Medical University (CN)
- Peking University People's Hospital (CN)
- First Affiliated Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Journal of Cardiovascular Development and Disease
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3390/jcdd13110613
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China